Latest:
Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Arndt Vogel, MD
Latest:
Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study
This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).
Arnold M. Markoe, MD
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?
A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Arpana M. Naik, MD
Latest:
Dr. Naik on Surgical Approaches in Patients With Breast Cancer
Arpana M. Naik, MD, associate professor of surgery, Division of Surgical Oncology, School of Medicine, Oregeon Health and Science University, discusses surgical approaches in the treatment of patients with breast cancer.
Art Rastinehad, DO
Latest:
Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy
Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
Arthur Lemay, RPh
Latest:
Merging Community Practices With an Academic Cancer Center
Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Arti Hurria, MD
Latest:
Dr. Hurria on Challenges Facing the Geriatric Population with Breast Cancer
Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.